Magaldrate (malumix) is a chemical combination of magnesium and aluminum hydroxides used an antacid. It has a rapid action, high acid consuming capacity. Studies in vitro showed that magaldrate (malumix) possessed some antipepsin activity. At pH = 1.5 proteolysis was inhibited 55% by malumix. Pretreatment with Malumix suspension 30 minutes before ethanol reduced the severity and extent of gastric mucosal lesions at dose-dependent manner. Magaldrate (malumix) had not acute toxicity in vivo test.
Peptic Ulcer ; Therapeutics ; Magaldrate ; Pharmaceutical Preparations

Magaldrat, a chemical combination of aluminum and magnesium hydroxides was synthesized from aluminum compounds and magnesium sulfate. The factors, which influence the result, have been investigated. The quality of magaldrate has also been analyzed following the standards of USP XXIII. The product showed low acute and chronic toxicity in vivo.
Stomach Diseases ; Aluminum ; therapeutics ; Pharmaceutical Preparations

The acute toxicity of Bimix (CBS) has been tested on mice at the dose of 1.25g/kg once time daily. This dose was equivalent to dose of 73 times the daily therapeutic dose on body weight. No toxic effects were seen. Acute toxicity appeared to be virtually nil. The semi-acute has also tested on mice at the dose 0.125g/kg once daily for 45 days. No accumulated toxicity was observed. No lesion or damage were apparent in the liver and kidneys. The results of experiment showed that CBS could be used for a long time with a little change on haematology and biochemical indices
Pharmaceutical Preparations ; toxicity

Bimix - a produce of CBS have been prepared and tested for inhibitory activity against E. coli, P. aeruginosa, Staphylococcus aureus and Streptococcus faecalis. The efficacy of Bimix also was compared with Gastrostat and Trymo. They had only bactericidal activity in Streptococcus - faecalis. The range of the minimum inhibitory concentration (MIC) for CBS (Bimix) against some H. pylori was 2-32 g/ml
Helicobacter pylori ; therapy ; Anti-Bacterial Agents ; tablets

Malumix, an antiacid uncoated tablet, contains Magaldrate as the biological active agent. Its optimal formula was established by using the artificial intelligent software CAD/CHEM 4.6, based on the experimental data of nine designed formulae. The experimental properties of the above dosage form were almost the same in comparison with its predicted ones.
Chemistry, Pharmaceutical ; Artificial Intelligence

The first Viet Nam baby born from intracytoplasmic sperm injection using testicular sperm from impaired spermatogenesis testes in 1/3/2004. There was approximately 50000 sperm after preparation, among them 20% was motile. From 12 retrieved oocytes, 11 were mature and therefore injected. Five oocytes fertilized and developed into 4 embryos. Embryo transfer was carried out for all 4 embryos. One embryo implanted and kept growing till the 37th week of pregnancy. Patient underwent ceasarian section
Spermatogenesis ; Sperm Retrieval ; Sperm Injections, Intracytoplasmic

A new compound, 3β-acetoxylanosta-7,9(11),24-triene-26-al (3), and seven known compounds (1 – 2 and 4 – 8) were isolated from Ganoderma tropicum (Jung.) Bres. collected in Tay Nguyen, Vietnam. The structures of these compounds were determined by one- and two-dimensional nuclear magnetic resonance spectroscopy, electrospray ionization mass spectrometry (ESI-MS), and high-resolution ESI-MS, and by comparison with literature data. All of the isolated compounds were tested for nitroblue tetrazolium (NBT) reduction activity in Saccharomyces cerevisiae-stimulated RAW 246.7 cells. Among them, compounds 2 – 4 and 6 – 8 enhanced the NBT reduction in a dose-dependent manner.

A new compound, 3β-acetoxylanosta-7,9(11),24-triene-26-al (3), and seven known compounds (1 – 2 and 4 – 8) were isolated from Ganoderma tropicum (Jung.) Bres. collected in Tay Nguyen, Vietnam. The structures of these compounds were determined by one- and two-dimensional nuclear magnetic resonance spectroscopy, electrospray ionization mass spectrometry (ESI-MS), and high-resolution ESI-MS, and by comparison with literature data. All of the isolated compounds were tested for nitroblue tetrazolium (NBT) reduction activity in Saccharomyces cerevisiae-stimulated RAW 246.7 cells. Among them, compounds 2 – 4 and 6 – 8 enhanced the NBT reduction in a dose-dependent manner.

Background: s/Aims: Parenchymal-sparing anatomical hepatectomy (Ps–AH) based on portal ramification of the right anterior section (RAS) is a new technique to avoid unnecessarily transecting too much liver parenchyma, especially in cases of major anatomical hepatectomy. Methods: We prospectively assessed 26 patients with primary hepatic malignancies having undergone major Ps–AH based on portal ramification of the RAS from August 2018 to August 2022 (48 months). The perioperative indications, clinical data, intra-operative index, pathological postoperative specimens, postoperative complications, and follow-up results were retrospectively evaluated. Results: Among the 26 patients analyzed, there was just one case that had intrahepatic cholangiocarcinoma The preoperative level of α– Fetoprotein was 25.2 ng/mL. All cases (100%) had Child–Pugh A liver function preoperatively. The ventral/dorsal RAS was preserved in 19 and 7 patients, respectively. The mean surgical margin was 6.2 mm. The mean surgical time was 228.5 minutes, while the mean blood loss was 255 mL. In pathology, 5 cases (19.2%) had microvascular invasion, and in the group of HCC patients, 92% of all cases had moderate or poor tumor differentiation. Six cases (23.1%) of postoperative complications were graded over III according to the Clavien–Dindo system, including in three patients resistant ascites or intra-abdominal abscess that required intervention. Conclusions Parenchymal-sparing anatomical hepatectomy based on portal ramification of the RAS to achieve R0-resection was safe and effective, with favorable short-term outcomes. This technique can be used widely in clinical practice.

Background: s/Aims: Parenchymal-sparing anatomical hepatectomy (Ps–AH) based on portal ramification of the right anterior section (RAS) is a new technique to avoid unnecessarily transecting too much liver parenchyma, especially in cases of major anatomical hepatectomy. Methods: We prospectively assessed 26 patients with primary hepatic malignancies having undergone major Ps–AH based on portal ramification of the RAS from August 2018 to August 2022 (48 months). The perioperative indications, clinical data, intra-operative index, pathological postoperative specimens, postoperative complications, and follow-up results were retrospectively evaluated. Results: Among the 26 patients analyzed, there was just one case that had intrahepatic cholangiocarcinoma The preoperative level of α– Fetoprotein was 25.2 ng/mL. All cases (100%) had Child–Pugh A liver function preoperatively. The ventral/dorsal RAS was preserved in 19 and 7 patients, respectively. The mean surgical margin was 6.2 mm. The mean surgical time was 228.5 minutes, while the mean blood loss was 255 mL. In pathology, 5 cases (19.2%) had microvascular invasion, and in the group of HCC patients, 92% of all cases had moderate or poor tumor differentiation. Six cases (23.1%) of postoperative complications were graded over III according to the Clavien–Dindo system, including in three patients resistant ascites or intra-abdominal abscess that required intervention. Conclusions Parenchymal-sparing anatomical hepatectomy based on portal ramification of the RAS to achieve R0-resection was safe and effective, with favorable short-term outcomes. This technique can be used widely in clinical practice.